# Ascendis Pharma A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Ascendis Pharma A/S). ## Overview Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies built on its TransCon technology platform. The company is headquartered in Hellerup, Denmark and operates with additional facilities in Europe and the United States. ## Products & services • TransCon-based prescription therapies • SKYTROFA for pediatric growth hormone deficiency • YORVIPATH for hypoparathyroidism • YUVIWEL ophthalmic therapy • Biopharmaceutical R&D and clinical development - **Commercialized therapies** (70%) — Approved medicines sold in key markets, including SKYTROFA, YORVIPATH and YUVIWEL. - **Pipeline and clinical development** (20%) — TransCon-based programs in development for endocrine and other therapeutic areas. - **Technology platform licensing and collaborations** (10%) — Use of the TransCon platform in partnered or collaborative programs. - TransCon-based prescription therapies - SKYTROFA for pediatric growth hormone deficiency - YORVIPATH for hypoparathyroidism - YUVIWEL ophthalmic therapy - Biopharmaceutical R&D and clinical development ## Customers Ascendis sells prescription medicines used by specialists who treat rare endocrine and related disorders. Its end customers are patients, but purchasing and access are driven by hospitals, specialty physicians, payers and pharmacy distribution channels. The business depends on adoption by clinicians and reimbursement decisions that support access to specialty therapies. - **Specialist physicians** (primary) — Endocrinologists and other specialists prescribe the company's therapies for rare endocrine diseases. - **Patients with rare diseases** (primary) — Patients use the company's medicines for chronic endocrine conditions requiring ongoing treatment. - **Payers and reimbursement systems** (primary) — Insurers and national health systems determine coverage, access and formulary positioning. - **Hospitals and specialty pharmacies** (secondary) — These channels distribute and administer specialty medicines to end patients. - Endocrinologists treating pediatric growth hormone deficiency - Specialists managing hypoparathyroidism and related disorders - Patients accessing specialty prescription medicines through payers - Hospitals, clinics and specialty pharmacies distributing therapies - Reimbursement decision-makers that determine patient access ## Geography Ascendis is headquartered in Denmark and describes itself as a global biopharmaceutical company with additional facilities in Europe and the United States. The available filing excerpt does not provide a country revenue split, but the company’s operational footprint indicates a transatlantic structure that supports development, commercialization and regulatory activity in multiple markets. - Headquartered in Hellerup, Denmark - Additional facilities in Europe and the United States - Publicly listed on Nasdaq Global Select Market in the U.S. - Global commercial and development footprint - No country revenue split disclosed in excerpts ## Strategy Ascendis’ strategy is centered on applying the TransCon platform to create differentiated therapies with best-in-class potential in unmet medical needs. The company pairs internal R&D with commercial execution for approved products, while extending the platform across additional endocrine and specialty disease opportunities. - **Expand the TransCon pipeline** (long-term) — The platform is the core source of long-term product generation and differentiation. - **Grow commercial brands** (medium-term) — Approved products need physician adoption, access and repeat prescribing to scale. - **Strengthen global operating capabilities** (medium-term) — A transatlantic footprint supports development, regulatory and commercial execution. - Advance TransCon-based programs into approved therapies - Build commercial franchises around rare disease products - Expand the platform across additional indications - Maintain a global operating model across Europe and the U.S. - Use specialist focus to support adoption and market access ## Risks The business faces the usual biopharma risks around clinical development, regulatory approval, commercialization and reimbursement, all of which can delay or limit value creation. Because Ascendis depends on a small set of specialty therapies and a platform approach, adoption, safety, competition and access dynamics can have an outsized impact on performance. - **Clinical development failure** [high] — The platform depends on successful trials to create new approved therapies. - **Regulatory approval risk** [high] — Biopharmaceutical products require approvals and post-approval compliance. - **Market access and reimbursement pressure** [high] — Specialty drugs often depend on payer coverage and formulary placement. - **Product concentration** [high] — A limited commercial portfolio creates sensitivity to one product's performance. - **Competition in rare disease therapeutics** [medium] — Competing drugs and future entrants can affect physician choice and pricing. - Clinical trial failure or delay can halt pipeline value creation - Regulatory setbacks can postpone approvals and launches - Reimbursement pressure can limit specialty-drug access - Concentration in few products raises launch and adoption risk - Competitive therapies can reduce prescribing and pricing power - Foreign exchange and cross-border operations add complexity ## Accounting Important accounting judgments include sales deductions, which the company explicitly says are updated using estimates and assumptions. The company also adjusts for derivative liabilities related to convertible notes and the one-time recognition of deferred tax assets, both of which can move reported profit even though they are not part of core operating performance. - **Sales deductions estimates** — Affects reported net revenue and quarter-to-quarter comparability - **Convertible note derivative liabilities** — Can create non-operating gains or losses in profit - **Deferred tax assets** — Can cause one-time tax benefits and distort period comparison - **IFRS 18 transition** — May alter profit subtotal presentation without changing economics - Sales deductions rely on estimates and can change revenue timing - Derivative liabilities on convertible notes create fair-value volatility - Deferred tax asset recognition can create one-time profit effects - IFRS 18 adoption may change presentation of profit subtotals - Foreign currency balances can affect cash and earnings translation --- *Last updated: 2026-09-28T11:57:43.781697+00:00*